DINESH

Nephrocare Health Services

Industry: Healthcare
Latest CMP 660
Today's Change ▼ -0.55%
52-Week High / Low 765 | 449
Price Date: 30-Sep-2026
Recommendation Buy
Target Price 1,589
Expected Upside 55.2%
Forecast Horizon 2 Years
Historical CAGR Not Available
1,000 Invested —
Today's Value —
Investment Period < 5 Years

Stock Snapshot

Post Results Return
+4.6%
Mild Positive Re-rating
1-Year Target Price
1,290
2-Year Target Price
1,589
52-Week High / Low
765 / 449
20-Day Return
-6.7%
Market Cap (Cr.)
6,621
Current PE
113.6
P/BV Ratio
5.9
Dividend Yield
—
Industry PE
60.9

Price Performance

Vista Outlook

Basis of our Recommendation

Nephrocare Health Services is strategically positioning itself as a global leader in dialysis care, with management emphasizing aggressive international expansion that now constitutes 42% of total revenue. This shift is critical as it not only diversifies revenue streams but also enhances margins through shorter payback periods in new markets like Kazakhstan and Saudi Arabia. Vista's financial outlook reflects this positive trajectory, forecasting strong double-digit revenue and earnings growth through FY29, supported by a disciplined capital allocation strategy and operational efficiencies. The healthcare sector's stable pricing power and increasing demand for organized tertiary care further bolster this outlook. However, potential headwinds include regulatory risks and operational challenges in managing a high-fixed-cost business. Over the next 12-24 months, key opportunities lie in expanding the asset-light model and capturing market share in under-penetrated regions, while watchpoints include navigating reimbursement dependencies and international tender delays

👍 Why We Like This Stock

  • Aggressive scaling of high-margin international operations is driving revenue diversification and margin expansion
  • Management's disciplined capital allocation and focus on operational efficiency position the company for sustained double-digit growth
  • The healthcare sector's increasing demand for organized services supports Nephrocare's strategic initiatives

⚠ Things To Watch Out For

  • Regulatory dependence on government reimbursement poses risks to profitability and operational stability
  • Potential delays in international tender processes could hinder expansion efforts
  • Challenges associated with managing a high-fixed-cost business may impact margin performance

Key Parameters

Balance Sheet Strength
Stable Financial Structure
Market Share
Stable
Industry Outlook
Weakening
Analyst View
Strong Buy
Dividend History
No Dividend History
FII Holdings
Reducing

Financial Snapshot

View Technicals Analysis →
Actuals Forecast
FY24 FY25 FY26 FY27 FY28
Revenue (Cr.) 566 756 999 1,223 1,521
Profit Before Tax (Cr.) 33 86 97 142 190
PBT Margin 5.8% 11.4% 9.7% 11.6% 12.5%
Net Profit (Cr.) 31 69 62 107 143
Earnings Per Share 3.1 6.9 6.2 10.6 14.2

Analyst Recommendations

Broker Recommendation Target Price Date
ICICI Securities ▲ Buy 825 08-Sep-2026
Consensus Recommendation ▲ Strong Buy
Consensus Target 825
Coverage 1 Analysts
Analysts' Viewpoint
Nephroplus is capitalizing on its successful Philippines model to drive international growth, with plans to enter new markets every 12-18 months. This strategy enhances margins and capital efficiency, with international operations offering higher per-session realizations and shorter payback periods. Key risks include currency volatility and competitive pressures in the dialysis market. Future catalysts include potential contract wins in Saudi Arabia and strategic expansion in Central Asia through recent acquisitions.

Company Overview

Show Company Profile

Nephrocare Health Services Limited provides dialysis healthcare services through a chain of kidney care clinics and dialysis centers in India, Uzbekistan, Nepal, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. The company was incorporated in 2009 and is based in Hyderabad, India.